4D Molecular Therapeutics reported quarterly EPS of $0.43, beating the Zacks consensus of -$0.53 by $0.96 and reversing last year's -$0.90 loss. The quarter represents a $1.33 improvement year-over-year and marks a move to profitability, which is likely to be viewed positively by equity investors.
4D Molecular Therapeutics reported quarterly EPS of $0.43, beating the Zacks consensus of -$0.53 by $0.96 and reversing last year's -$0.90 loss. The quarter represents a $1.33 improvement year-over-year and marks a move to profitability, which is likely to be viewed positively by equity investors.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
strongly positive
Sentiment Score
0.60
Ticker Sentiment
